These findings also prompt the investigation of the DDR pathways in spontaneous LFS MBs or even in non-syndromic MBs-SHH/TP53-mutant in order to consider PARP inhibitors as potential therapy for this very aggressive subgroup of MBs. The gene discussed is TP53; the disease is Mobius syndrome.